Where can I listen to this podcast?

This podcast is available on 8 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

Yes, this podcast regularly features guests.

GHAPPcast

Claim This Podcast

by Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)

158 episodes

Updated Daily

Accepts GuestsHas SponsorsLocation 🇺🇸

Podcast Authority

Beta

FairBased on show quality, social media presence, reviews, charts, and more

Quality86

Social0

YouTube0

Engagement0

Learn more

Podcast Overview

This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).   Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).

Language

🇺🇲

Publishing Since

6/14/2023

Visit Website View on Apple Podcasts RSS Feed

🇺🇸 Charts #3

Outreach generated

Apple 142

Spotify 827

Instant mention tracking

Perfect fit!

Unlock The Full Podcast Authority Score Report

See how your podcast performs across key metrics

Podcast Authority

Beta

FairBased on show quality, social media presence, reviews, charts, and more

Quality86

Social0

YouTube0

Engagement0

Learn more

Excellent Areas

Good Performance

Growth Opportunities

excellent

Publishing Consistency

Every 8 days

Performing excellently!

poor

Episode Thumbnails

Recommendations available

Unlock the full report to see detailed tips

+16 More Metrics

Unlock comprehensive insights including:

• YouTube presence analysis
• Social media reach metrics
• RSS compliance scoring
• Podcast 2.0 features
• Technical standards

What's Included in Your Full Report

Detailed Analytics

Complete breakdown of all 19 authority metrics
Personalized recommendations for each metric
Industry benchmarks and comparisons
Technical RSS feed analysis and compliance scoring

Growth Strategies

Step-by-step action plans for improvement
Quick wins to boost your score immediately
Pro tips from successful podcasters

Get your free podcast insights report

See how your show performs across every key metric

Instant delivery

No spam

Attract Better Guests

High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.

Secure Sponsorships

Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.

Grow Your Audience

Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.

Reach the team behind GHAPPcast

Verified contact details for this show aren't on file yet — sign up to get notified when they land.

Recent Episodes

$Episode thumbnail for Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease$

June 9, 2026

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC, from the University of California San Diego, provide a comprehensive overview of the SEQUENCE trial, a landmark head-to-head study comparing risankizumab and ustekinumab in patients with moderate to severe Crohn’s disease who had previously failed anti-TNF therapy. The discussion explores the trial design, patient population, dosing strategies, primary and secondary endpoints, and the significance of efficacy assessor blinding in an open-label study.Sharon and Angelina review key findings demonstrating the superiority of risankizumab over ustekinumab across multiple clinical and endoscopic outcomes, including clinical remission, endoscopic response, corticosteroid-free remission, and long-term disease control. They also discuss the importance of objective disease assessment using centrally read endoscopy and the role of steroid tapering in evaluating treatment success. Safety outcomes are examined, highlighting the absence of new safety signals and reinforcing the established safety profile of risankizumab.This educational video is designed for gastroenterology nurse practitioners, physician assistants, and other healthcare professionals seeking practical insights into evidence-based treatment selection for Crohn’s disease. Viewers will gain a deeper understanding of how the SEQUENCE study may influence treatment positioning of IL-23 therapies in anti-TNF-experienced patients and how emerging long-term extension data continue to support durable clinical remission and endoscopic improvement with risankizumab.

June 2, 2026

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data evaluating the efficacy and safety of guselkumab in adults with moderate to severe ulcerative colitis. This discussion highlights approximately two years of follow-up data, offering healthcare providers valuable insight into the long-term durability of treatment response, clinical remission, endoscopic improvement, and overall safety outcomes associated with guselkumab maintenance therapy. Jamie walks through the key findings from the ongoing multicenter extension study, including sustained clinical remission rates, corticosteroid-free remission, endoscopic healing, and histologic-endoscopic mucosal improvement through week 92. The video also reviews the maintenance dosing strategies of guselkumab, including 100 mg every 8 weeks and 200 mg every 4 weeks, and discusses how patients who responded during earlier phases of treatment maintained those responses over time. In addition, the presentation covers important long-term safety findings, including rates of serious infections and adverse events observed throughout the study. This video is designed for gastroenterology APPs, nurse practitioners, physician assistants, gastroenterologists, and healthcare professionals looking to stay current on emerging ulcerative colitis therapies, long-term biologic data, and evolving treatment goals in inflammatory bowel disease (IBD). For more educational content on ulcerative colitis, Crohn’s disease, gastroenterology, and hepatology, visit the GHAPP Digital Hub and the GHAPP ACE app.

May 28, 2026

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory Bowel Disease Center, discusses an important question in Crohn’s disease treatment. This overview breaks down the key findings from the GALAXI and GRAVITI clinical trials in a clear, practical way, helping healthcare providers better understand the effectiveness and safety of both treatment approaches for patients with moderate to severe Crohn’s disease. Angelina explains the differences between IV and subcutaneous induction dosing, maintenance treatment options, and how these choices can support shared decision-making between providers and patients. Whether patients are new to advanced therapies or have previous biologic experience, this discussion highlights how both induction options may provide strong results without compromising safety. This video is designed for gastroenterology APPs, nurse practitioners, physician assistants, gastroenterologists, and healthcare professionals looking for practical insights into Crohn’s disease management and evolving IBD treatment strategies. For more GI and hepatology education, visit the GHAPP Digital Hub and the GHAPP ACE app.

158 total episodes available

Recent guests on GHAPPcast

Guests from recent episodes — sign up to see every guest that has ever appeared on this show.

Kristina Skarbinski

Guest

Christina Hanson

Guest

Patrick Horne

Guest

HoChong Gilles

Guest

Sarah Dawkins

Guest

Monica Nandwani

Guest

Kim Orleck

Guest

Amy Ladewski

Guest

Hannah Ryan

Guest

Sarah Enslin

Guest

See every guest on GHAPPcast

Similar Podcasts

Discover related shows you might enjoy

The Curbsiders Internal Medicine Podcast

American Journal of Gastroenterology Author Podcasts

American College of Gastroenterology

Evidence-Based GI: An ACG Publication and Podcast

American College of Gastroenterology

NEJM This Week

NEJM Group

Gastroenterology Learning Network

The Gut Health Podcast

Kate Scarlata and Megan Riehl

Gastro Girl

Gastro Girl Inc

JAMA Editors' Summary

JAMA Network

Gut Podcast

BMJ Group

UEG Talks

UEG United European Gastroenterology

SERIALously

Annie Elise & Audioboom Studios

Park Predators

Audiochuck

The Daily

The New York Times

The Journal.

The Wall Street Journal & Spotify Studios

Deep-dive analytics for GHAPPcast

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is GHAPPcast?: This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).

Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).
How often does this podcast release new episodes?: This podcast updates daily.
Where can I listen to this podcast?: This podcast is available on 8 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Does this podcast accept guests?: Yes, this podcast regularly features guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.